Sirolimus for Massive Polycystic Liver

• Status: Unknown status
• Trial end date: 2015-08-01

Summary

The purpose of this study is to evaluate the effectiveness and safety of Sirolimus in reducing liver volume in autosomal dominant polycystic kidney disease.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Everolimus; Sirolimus